

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* NEFF P SHERRILL _____ (Last) (First) (Middle) C/O QUAKER BIOVENTURES 2929 ARCH STREET, CIRA CENTRE _____ (Street) PHILADELPHIA PA 19104 _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS INC [FOLD]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner _____ Officer (give title below) Other (specify below)		
			3. Date of Earliest Transaction (Month/Day/Year) 06/05/2007			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person _____ Form filed by More than One Reporting Person		
			4. If Amendment, Date of Original Filed (Month/Day/Year)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/05/2007		C		1,419,762	A	(1)	1,419,762	I	By Partnership ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Convertible Preferred Stock	(1)	06/05/2007		C		396,825		08/16/2005	(1)	Common Stock	396,825	\$0	0	I	By Quaker Bioventures, L.P. ⁽²⁾
Series C Convertible Preferred Stock	(1)	06/05/2007		C		132,275		08/16/2005	(1)	Common Stock	132,275	\$0	0	I	By Garden State Life Sciences Venture Fund, L.P. ⁽³⁾
Series C Convertible Preferred Stock	(1)	06/05/2007		C		396,825		04/17/2006	(1)	Common Stock	396,825	\$0	0	I	By Quaker Bioventures, L.P. ⁽²⁾
Series C Convertible Preferred Stock	(1)	06/05/2007		C		132,275		04/17/2006	(1)	Common Stock	132,275	\$0	0	I	By Garden State Life Sciences Venture Fund, L.P. ⁽³⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C		135,586		09/13/2006	(1)	Common Stock	135,586	\$0	0	I	By Quaker Bioventures, L.P. ⁽²⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C		45,195		09/13/2006	(1)	Common Stock	45,195	\$0	0	I	By Garden State Life Sciences Venture Fund, L.P. ⁽³⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C		135,586		03/09/2007	(1)	Common Stock	135,586	\$0	0	I	By Quaker Bioventures, L.P. ⁽²⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C		45,195		03/09/2007	(1)	Common Stock	45,195	\$0	0	I	By Garden State Life Sciences Venture Fund, L.P. ⁽³⁾

Explanation of Responses:

- Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one for one basis upon the closing of Amicus Therapeutics, Inc's initial public offering on June 5, 2007.
- The reporting person is a member of Quaker BioVentures Capital, L.P., which is the general partner of Quaker BioVentures, L.P. Voting and investment power over these shares is exercised by Quaker BioVentures Capital, L.P. in its role as general partner and investment advisor of Quaker BioVentures, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 of for any other purpose.
- The reporting person is a member of Quaker BioVentures Capital, L.P., which is the general partner of Garden State Life Sciences Venture Fund, L.P. Voting and investment power over these shares is exercised by Quaker BioVentures Capital, L.P. in its role as general partner and investment advisor of Garden State Life Sciences Venture Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to

the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 of for any other purpose.

4. Consists of 1,064,822 shares held by Quaker BioVentures, L.P. and 354,940 shares held by Garden State Life Sciences Venture Fund, L.P. The reporting person is a member of Quaker BioVentures Capital, L.P., which is the general partner of Quaker BioVentures, L.P. and Garden State Life Sciences Venture Fund, L.P. Voting and investment power over these shares is exercised by Quaker BioVentures Capital, L.P. in its role as general partner and investment advisor of Quaker BioVentures, L.P. and Garden State Life Sciences Venture Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 of for any other purpose.

/s/ Sherrill Neff

06/06/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.